Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, licensing deals, and cash-burn projections often hide deep inside Inovio’s SEC paperwork. Between a 200-plus page annual report and frequent disclosures of study data, even seasoned biotech investors spend hours hunting for answers. If you’ve ever wondered, “Where can I find Inovio’s quarterly earnings report 10-Q filing?” or searched for “Inovio insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI reads every submission to EDGAR the instant it appears, transforming dense documents into clear, actionable summaries. Need the Inovio annual report 10-K simplified? Our AI links each figure to plain-English commentary. Looking for 8-K material events explained after a vaccine data release? Alerts arrive in real time. Form 4 insider transactions real-time updates show exactly when executives buy or sell shares, while our dashboards spotlight cash-runway trends and R&D spend across quarters.
Because Inovio’s business hinges on DNA plasmid technology and regulatory milestones, we connect filing types directly to your questions:
- Which clinical programs advanced this quarter? See the Inovio quarterly earnings report 10-Q filing.
- Did partnership revenue hit its benchmark? Our AI flags those lines for quick review.
- Want alerts on Inovio executive stock transactions Form 4 before data readouts? Notifications appear instantly.
- Need board-level pay details? The latest Inovio proxy statement executive compensation section is summarized and searchable.
Understanding Inovio SEC documents with AI means faster decisions and deeper insights. Get every Inovio SEC filing explained simply—only on Stock Titan.
Loop Industries, Inc. (Nasdaq: LOOP) has filed a high-detail 424(b)(5) prospectus supplement establishing a $15 million at-the-market (ATM) equity program through Roth Capital Partners. The company may periodically issue and sell common shares, with the sales agent receiving a 3.0% commission. Shares will be offered at prevailing market prices on Nasdaq or through negotiated transactions; no minimum sale amount is required.
Key figures include:
- Maximum aggregate offering: $15,000,000.
- Last reported share price (2 Jul 2025): $1.26.
- Current shares outstanding: 47.7 million; public float ≈ $16.1 million.
- Potential issuance: approx. 11.9 million new shares (based on the $1.26 reference price) raising pro forma shares outstanding to 59.6 million.
- Estimated dilution to new investors: $1.04 per share compared with adjusted tangible book value of $0.22.
Proceeds are earmarked for working capital, Infinite Loop™ facility capex, joint-venture financing and possible technology/licensing acquisitions. Loop remains a smaller reporting company and discloses substantial business and stock-specific risks, emphasising share-price volatility and future financing needs. There is no escrow arrangement; sales are at Loop’s sole discretion and may be suspended at any time.
Given the company’s public float below $75 million, sales are capped at one-third of float within any 12-month period under Form S-3 “Baby Shelf” rules; Loop confirms no prior offerings under this limitation in the past year. Shareholders face immediate dilution and potential future dilution from outstanding preferred stock, options and RSUs (together >13 million additional shares).
Inovio Pharmaceuticals, Inc. (Nasdaq: INO) has filed a preliminary prospectus supplement under its effective shelf to raise capital through a combined offering of: (i) shares of common stock or pre-funded warrants (exercise price $0.001) in lieu of common stock, (ii) Series A warrants, and (iii) Series B warrants. Every share (or pre-funded warrant) will be sold together with one Series A warrant and one Series B warrant, although the securities are immediately separable upon issuance.
- Pricing & size: Key economics—number of securities, combined public price, underwriting discount, and gross/net proceeds—remain blank pending final marketing, but the filing authorizes a 30-day overallotment option for additional shares and warrants.
- Warrant profile: • Series A warrants are exercisable immediately, expire on the earlier of (a) 30 days after FDA accepts a Biologics License Application (BLA) for INO-3107 or (b) 12 months after issuance; • Series B warrants are exercisable immediately and expire five years after issuance. Neither series will be listed, limiting liquidity.
- Use of proceeds: Management plans to direct funds to (1) advancement of its DNA-medicine clinical pipeline—including a rolling BLA submission for lead asset INO-3107 in recurrent respiratory papillomatosis expected to begin mid-2025, (2) potential commercial launch preparation for INO-3107 if approved, and (3) general corporate purposes.
- Dilution & risk: The company warns that investors will incur immediate dilution; further dilution could arise from outstanding equity awards (≈2.6 m shares), legacy warrants (≈10 m at $3.76) and future ATM sales ($57.9 m capacity). Inovio remains a clinical-stage biotech with no product revenue, significant accumulated deficits, and multiple R&D, regulatory, manufacturing and financing risks.
- Corporate status: Inovio is a “smaller reporting company,” enabling reduced SEC disclosure. Piper Sandler is sole book-running manager.
Because amounts are placeholders, the filing primarily signals intent to strengthen the balance sheet ahead of key regulatory catalysts rather than conveying finalized financial impact.
Schedule 13D/A Amendment No. 6 for Gabelli Healthcare & Wellness Rx Trust (GRX) Preferred Shares discloses updated ownership information for multiple Gabelli-related entities and individuals.
Aggregate ownership: The Reporting Persons now hold 1,514,000 preferred shares, equal to 45.49 % of the 3,328,500 shares outstanding as of 30 Jun 2025. Key positions include:
- Associated Capital Group (AC): 400,000 shares – 12.02 %
- GAMCO Investors (GBL): 400,000 shares – 12.02 %
- Mario J. Gabelli (individual): 400,000 shares – 12.02 %
- Gabelli Foundation: 314,000 shares – 9.43 %
Recent transactions (26 Jun 2025): Several entities surrendered a total of 1,440,000 preferred shares (Series E & Series G) at $10.00 per share under the Fund’s put right to redeem up to 100 % of its outstanding cumulative preferred stock. The largest single surrender was 830,000 shares by Mario J. Gabelli.
Post-transaction, the group retains a controlling minority of the preferred class, maintaining significant influence over matters requiring preferred-shareholder approval. All reporting persons exercise sole voting and dispositive power over their respective holdings; no shared power is reported. No new legal proceedings or changes in control arrangements were disclosed.
Implications for investors: While the surrender materially reduces absolute ownership, the group’s collective stake remains large at 45 %. The buy-back at par ($10) may signal limited upside in the current preferred valuation and could affect liquidity of the remaining float. However, continued alignment of interests between the Gabelli entities and preferred shareholders persists.
FAQ
What is the current stock price of Inovio Pharmaceu (INO)?
What is the market cap of Inovio Pharmaceu (INO)?
What is Inovio Pharmaceuticals' core technology?
How do Inovio's immunotherapies work?
Which medical areas does Inovio focus on?
What makes Inovio's approach unique within the biotech industry?
How does Inovio generate revenue?
What role do collaborations play in Inovio’s strategy?
How is Inovio positioned in the market?
Are Inovio’s therapies supported by clinical evidence?
What regulatory achievements has Inovio secured?
How does Inovio address challenges in traditional immunotherapy platforms?
